Drug intelligence / Profile preview

mineralocorticoid receptor antagonist (Nucien Pharmaceuticals)

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules

Overview

Mineralocorticoid receptor antagonist (Nucien Pharmaceuticals) is a small molecule drug candidate currently in the preclinical stage of development. Developed by Nucien Pharmaceuticals, it is intended for the treatment of diabetic nephropathy, hypertension, and heart failure. The drug's mechanism involves selectively antagonizing the mineralocorticoid receptor (MR), thereby preventing the binding of aldosterone and inhibiting downstream pathways that lead to inflammation, oxidative stress, and fibrosis in renal and cardiovascular tissues. This therapeutic approach aims to provide organ protection and slow the progression of chronic kidney and heart diseases by mitigating the deleterious effects of overactivated aldosterone signaling.

Other names: MR拮抗剂Mineralocorticoid receptor antagonist

Targets

MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on mineralocorticoid receptor antagonist (Nucien Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mineralocorticoid receptor antagonist (Nucien Pharmaceuticals).

Explore the full profile